openPR Logo
Press release

Lawsuit filed for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM)

05-19-2022 04:40 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares.

A lawsuit was filed on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares.

An investor, who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Axsome Therapeutics, Inc.

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and for certain investors are short and strict deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

New York based Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The Company is developing, among other product candidates, AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine for the acute treatment of migraine.

The plaintiff says that Axsome Therapeutics, Inc consistently touted AXS-07's regulatory and commercial prospects in anticipation of the Company's submission a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for AXS-07 for the acute treatment of migraine (the "AXS-07 NDA") based on the drug's positive results in two Phase 3 trials and that , unbeknownst to investors, the Company's preparation and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and control ("CMC") issues.
On November 5, 2020, Axsome Therapeutics, Inc reported the Company's third quarter 2020 results. That press release disclosed that the Company "plans to submit the [AXS-07] NDA to the FDA in the first quarter of 2021, versus previous guidance of the fourth quarter of 2020, to allow for inclusion of supplemental manufacturing information to ensure a robust submission package."

Then, on April 25, 2022, Axsome Therapeutics, Inc disclosed in a filing with the U.S. Securities and Exchange Commission that, "[o]n April 22, 2022, Axsome . . . was informed by the [FDA] that [CMC] issues identified during the FDA's review of the Company's [NDA] for its AXS-07 product candidate for the acute treatment of migraine are unresolved." That filing also disclosed that "[b]ased upon the time remaining in the NDA review cycle, the Company expects to receive a Complete Response Letter [('CRL')] with respect to this NDA on or about the Prescription Drug User Fee Act target action date of April 30, 2022."

Finally, on May 2, 2022, Axsome Therapeutics, Inc announced that it received a CRL from the FDA regarding the AXS-07 NDA for the acute treatment of migraine. According to the Company, "[t]he principal reasons given in the CRL relate to [CMC] considerations" including "the need for additional CMC data pertaining to the drug product and manufacturing process."

Shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) declined from $47.40 per share on April 5, 2022, to as low as $24.13 per share on May 12, 2022.

According to the complaint the plaintiff alleges on behalf of purchasers of Axsome Therapeutics, Inc. (NASDAQ: AXSM) common shares between December 30, 2019 and April 22, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 30, 2019 and April 22, 2022, the defendants made false and/or misleading statements and/or failed to disclose that Axsome's CMC practices were deficient with respect to AXS-07 and its manufacturing process, that as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline, that the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA, that accordingly, the FDA was unlikely to approve the AXS-07 NDA, that as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) here

News-ID: 2629073 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in GrafTech International Ltd. (NYSE: EAF) over potential Wrongdoing
Investigation announced for Investors in GrafTech International Ltd. (NYSE: EAF) …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of GrafTech International Ltd. Investors who are current long term investors in GrafTech International Ltd. (NYSE: EAF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: EAF stocks follows a lawsuit filed against GrafTech International
Lawsuit filed for Long-Term Investors of Amplitude, Inc. (NASDAQ: AMPL) against certain Directors of Amplitude, Inc.
Lawsuit filed for Long-Term Investors of Amplitude, Inc. (NASDAQ: AMPL) against …
A long-term investor in shares of Amplitude, Inc. (NASDAQ: AMPL) filed a lawsuit against certain directors of Amplitude, Inc. over alleged breaches of fiduciary duties. Investors who are current long term investors in Amplitude, Inc. (NASDAQ: AMPL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The plaintiff alleges certain current and former insiders of Amplitude, Inc. profited from misrepresentations they made about
Investigation announced for Investors who lost money with shares of GameStop Corp. (NYSE: GME)
Investigation announced for Investors who lost money with shares of GameStop Cor …
An investigation was announced for investors of GameStop Corp. (NYSE: GME) shares over potential securities laws violations by GameStop Corp. Investors who purchased shares of GameStop Corp. (NYSE: GME), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by GameStop Corp. regarding its business, its prospects and its operations were materially false and
Investigation announced for Long-Term Investors in shares of Brooge Energy Limited (NASDAQ: BROG) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Brooge Energy Limit …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Brooge Energy Limited. Investors who are current long term investors in Brooge Energy Limited (NASDAQ: BROG) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: BROG stocks follows a lawsuit filed against Brooge

All 5 Releases


More Releases for Axsome

Investigation announced for NASDAQ: AXSM Investors over possible Wrongdoing at A …
An investigation was announced for clong-term investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) concerning potential breaches of fiduciary duties by certain directors and officers of Axsome Therapeutics, Inc. Investors who are current long term investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on July 12, 2022 coming up in Lawsuit for Investors in Axsome Therapeut …
A deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) over alleged securities laws violations by Axsome Therapeutics, Inc. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and there are strict and short deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in Axsome Therapeutics, Inc. (NA …
Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Axsome Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. New York based Axsome Therapeutics,
Investigation announced for Investors in shares of Axsome Therapeutics, Inc. (NA …
An investigation was announced over potential securities laws violations by Axsome Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Axsome Therapeutics, Inc. regarding its business, its prospects and its operations were
Depression - Pipeline Review & Swot Analysis by key Manufacturers Atai Life Scie …
A new independent 668 page research with title 'Depression - Pipeline Review, H1 2020' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, South America, Asia & Pacific, Europe & MEA (Middle East and Africa) and important players/vendors such as Acadia Pharmaceuticals Inc, Adamed Sp zoo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aision Biotechnologies Inc, Alkermes Plc etc.
Meloxicam Market Global Sales, Revenue, Price and Gross Margin Forecast To 2028 …
This detailed market study covers meloxicam market growth potentials which can assist the stake holders to understand key trends and prospects in meloxicam market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also